clinical trial · NCT07244341
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Metastatic Castration-resistant Prostate CancerValemetostatDarolutamide
brief summary
This study will assess the safety and tolerability of valemetostat in combination with darolutamide in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC).
started
Dec 3, 2025
primary completion
Jan 31, 2028
completion
Nov 30, 2029
last updated
May 15, 2026
official title
A Phase 1, Multicenter Trial Evaluating the Safety, Tolerability, and Efficacy of Valemetostat (DS-3201) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol